Biocon gets DCGI nod to market biosimilar trastuzumab in India

27-11-2013 Economic TimesComments (0)

BiosimilarsOncology

Biotechnology major Biocon today said it has received approval from the Indian drug regulator to market its biosimilar trastuzumab developed jointly with Mylan for treating breast cancer. "The company has received market authorisation from ...

Read more on Economic Times

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top